Abstract
To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.
| Original language | English |
|---|---|
| Pages (from-to) | 164-172 |
| Number of pages | 9 |
| Journal | European Journal of Haematology, Supplement |
| Volume | 43 |
| Issue number | 51 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. / Gulati, S. C.; Shimazaki, C.; Lemoli, R. M.; Atzpodien, J.; Clarkso n, B. D.
In: European Journal of Haematology, Supplement, Vol. 43, No. 51, 1989, p. 164-172.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies
AU - Gulati, S. C.
AU - Shimazaki, C.
AU - Lemoli, R. M.
AU - Atzpodien, J.
AU - Clarkso n, B. D.
PY - 1989
Y1 - 1989
N2 - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.
AB - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0024935106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024935106&partnerID=8YFLogxK
M3 - Article
C2 - 2627987
AN - SCOPUS:0024935106
VL - 43
SP - 164
EP - 172
JO - Scandinavian journal of haematology. Supplementum
JF - Scandinavian journal of haematology. Supplementum
SN - 0902-4506
IS - 51
ER -